Eiger BioPharmaceuticals Inc

-0.01 (-0.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)209.14M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$3.32 Million
Adjusted EPS-$0.57
See more estimates
10-Day MA$6.72
50-Day MA$6.91
200-Day MA$8.13
See more pivots

Eiger BioPharmaceuticals Inc Stock, NASDAQ:EIGR

2155 Park Boulevard, 2155 Park Boulevard, Palo Alto, California 94306
United States of America
Phone: +1.650.272.6138
Number of Employees: 28


Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.